Higher PD-1 expression concurrent with exhausted CD8+ T cells in patients with de novo acute myeloid leukemia
To investigate the association between the T cell inhibitory receptor programmed death 1 (PD-1) and T cell exhaustion status in T cells from patients with acute myeloid leukemia (AML) and AML in complete remission (CR). Surface expression of PD-1 and the exhaustion and immunosenescence markers CD244...
Gespeichert in:
Veröffentlicht in: | Chinese journal of cancer research 2017-10, Vol.29 (5), p.463-470 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | To investigate the association between the T cell inhibitory receptor programmed death 1 (PD-1) and T cell exhaustion status in T cells from patients with
acute myeloid leukemia (AML) and AML in complete remission (CR).
Surface expression of PD-1 and the exhaustion and immunosenescence markers CD244 and CD57 on CD3+, CD4+ and CD8+ T cells from peripheral blood samples from 20 newly diagnosed, untreated AML patients and 10 cases with AML in CR was analyzed by flow cytometry. Twenty-three healthy individuals served as control.
A significantly higher percentage of PD-1+ cells were found for CD3+ T cells in the
AML group compared with healthy controls. In addition, an increased level of PD-1+CD8+ T cells, but not PD-1+CD4+, was found for CD3+ T cells in the
AML and AML-CR samples. A higher percentage of CD244+CD4+, CD244+CD8+, CD57+CD4+ and CD57+CD8+ T cells was found in CD3+ T cells in samples from those with
AML compared with those from healthy controls. Strong increased PD-1+CD244+ and PD-1+CD57+ co-expression was found for CD4+ and CD8+ T cells in the
AML group compared with healthy controls.
We characterized the major T cell defects, including co-expression of PD-1 and CD244, CD57-exhausted T cells in patients with
AML, and found a particular influence on CD8+ T cells, suggesting a poor anti-leukemia immune response in these patients. |
---|---|
ISSN: | 1000-9604 1993-0631 |
DOI: | 10.21147/j.issn.1000-9604.2017.05.11 |